Represented ALPHAEON as a selling stockholder in Evolus’ public offering of 4,000,000 shares of its common stock at a price of $20.00 per share. The offering consisted of 3,000,000 shares offered by Evolus and 1,000,000 shares offered by ALPHAEON. The offering resulted in net proceeds of approximately $56.4 million to Evolus and $18.8 million to ALPHAEON.
Evolus is a medical aesthetics company whose lead product is an injectable purified botulinum toxin A complex that will help treat glabellar lines and will compete with Allergan’s Botox. Evolus spun out of ALPHAEON, a social commerce company with the goal of transforming self-pay healthcare by leveraging the power of its professional network of physician specialists to drive lifestyle healthcare advancements, and improve patient experiences and outcomes in the wellness, beauty and performance sectors.
The Newport Beach-based deal team representing ALPHAEON included Marc Alcser and Jason Lee.